{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:02:41Z","timestamp":1789758161539,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Checkpoint-inhibitor immunotherapies have had a profound effect in the treatment of cancer by inhibiting down-regulation of T-cell response to malignancy. The cardiotoxic potential of these agents was first described in murine models and, more recently, in numerous clinical case reports of pericarditis, myocarditis, pericardial effusion, cardiomyopathy, and new arrhythmias. The objective of our study was to determine the frequency of and associated risk factors for cardiotoxic events in patients treated with immune checkpoint inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Medical records of patients who underwent immunotherapy with durvalumab, ipilimumab, nivolumab, and pembrolizumab at Wake Forest Baptist Health were reviewed. We collected retrospective data regarding sex, cancer type, age, and cardiovascular disease risk factors and medications. We aimed to identify new diagnoses of heart failure, atrial fibrillation, ventricular fibrillation\/tachycardia, myocarditis, and pericarditis after therapy onset. To assess the relationship between CVD risk factors and the number of cardiac events, a multivariate model was applied using generalized linear regression. Incidence rate ratios were calculated for every covariate along with the adjusted <jats:italic>P<\/jats:italic>-value. We applied a multivariate model using logistic regression to assess the relationship between CVD risk factors and mortality. Odds ratios were calculated for every covariate along with the adjusted <jats:italic>P<\/jats:italic>-value. Adjusted <jats:italic>P<\/jats:italic>-values were calculated using multivariable regression adjusting for other covariates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Review of 538 medical records revealed the following events: 3 ventricular fibrillation\/tachycardia, 12 pericarditis, 11 atrial fibrillation with rapid ventricular rate, 0 myocarditis, 8 heart failure. Significant risk factors included female gender, African American race, and tobacco use with IRR 3.34 (95% CI 1.421, 7.849; <jats:italic>P<\/jats:italic>\u2009=\u20090.006), IRR 3.39 (95% CI 1.141, 10.055; <jats:italic>P<\/jats:italic>\u2009=\u20090.028), and IRR 4.21 (95% CI 1.289, 13.763; <jats:italic>P<\/jats:italic>\u2009=\u20090.017) respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study revealed 34 significant events, most frequent being pericarditis (2.2%) and atrial fibrillation (2.0%) with strongest risk factors being female gender, African American race, and tobacco use. Patients who meet this demographic, particularly those with planned pembrolizumab treatment, may benefit from early referral to a cardio-oncologist. Further investigation is warranted on the relationship between CTLA-4 and PD-L1 expression and cardiac adverse events with ICIs, particularly for these subpopulations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40959-022-00130-5","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T09:06:57Z","timestamp":1646989617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Cardiotoxicity risk factors with immune checkpoint inhibitors"],"prefix":"10.1186","volume":"8","author":[{"given":"Zachary L.","family":"Brumberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max W","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Seals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujethra","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"issue":"17","key":"130_CR1","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33(17):1889\u201394. https:\/\/doi.org\/10.1200\/JCO.2014.56.2736.","journal-title":"J Clin Oncol"},{"issue":"11","key":"130_CR2","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","volume":"12","author":"G Kwok","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016;12(11):2777\u201389. https:\/\/doi.org\/10.1080\/21645515.2016.1199310.","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"130_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350. https:\/\/doi.org\/10.1038\/s41568-019-0116-x.","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"130_CR4","doi-asserted-by":"publisher","first-page":"E4223","DOI":"10.1073\/pnas.1617941114","volume":"114","author":"UA Ramagopal","year":"2017","unstructured":"Ramagopal UA, Liu W, Garrett-Thomson SC, Bonanno JB, Yan Q, Srinivasan M, et al. Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proc Natl Acad Sci U S A. 2017;114(21):E4223\u201332. https:\/\/doi.org\/10.1073\/pnas.1617941114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"130_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561\u201384. https:\/\/doi.org\/10.1038\/nrd4591.","journal-title":"Nat Rev Drug Discov"},{"issue":"21","key":"130_CR6","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691\u20137. https:\/\/doi.org\/10.1200\/JCO.2012.41.6750.","journal-title":"J Clin Oncol"},{"issue":"18","key":"130_CR7","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1609214.","journal-title":"N Engl J Med"},{"issue":"12","key":"130_CR8","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9(12):1477\u201383. https:\/\/doi.org\/10.1038\/nm955.","journal-title":"Nat Med"},{"issue":"5502","key":"130_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319\u201322. https:\/\/doi.org\/10.1126\/science.291.5502.319.","journal-title":"Science"},{"issue":"6","key":"130_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/intimm\/dxq026","volume":"22","author":"J Wang","year":"2010","unstructured":"Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y, Nakaki F, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol. 2010;22(6):443\u201352. https:\/\/doi.org\/10.1093\/intimm\/dxq026.","journal-title":"Int Immunol"},{"issue":"4","key":"130_CR11","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.4049\/jimmunol.181.4.2513","volume":"181","author":"JA Lucas","year":"2008","unstructured":"Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol. 2008;181(4):2513\u201321. https:\/\/doi.org\/10.4049\/jimmunol.181.4.2513.","journal-title":"J Immunol"},{"issue":"1","key":"130_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/jjco\/hyx154","volume":"48","author":"K Tajiri","year":"2018","unstructured":"Tajiri K, Aonuma K, Sekine I. Immune checkpoint inhibitor-related myocarditis. Jpn J Clin Oncol. 2018;48(1):7\u201312. https:\/\/doi.org\/10.1093\/jjco\/hyx154.","journal-title":"Jpn J Clin Oncol"},{"key":"130_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fcvm.2019.00003","volume":"6","author":"K Tajiri","year":"2019","unstructured":"Tajiri K, Ieda M. Cardiac Complications in Immune Checkpoint Inhibition Therapy. Front Cardiovasc Med. 2019;6:3. https:\/\/doi.org\/10.3389\/fcvm.2019.00003.","journal-title":"Front Cardiovasc Med"},{"key":"130_CR14","doi-asserted-by":"publisher","first-page":"794842","DOI":"10.1155\/2015\/794842","volume":"2015","author":"S Yun","year":"2015","unstructured":"Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015;2015:794842. https:\/\/doi.org\/10.1155\/2015\/794842.","journal-title":"Case Rep Oncol Med"},{"key":"130_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front Pharmacol. 2017;8:49. https:\/\/doi.org\/10.3389\/fphar.2017.00049.","journal-title":"Front Pharmacol"},{"key":"130_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40425-015-0048-2","volume":"3","author":"BP Geisler","year":"2015","unstructured":"Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4. https:\/\/doi.org\/10.1186\/s40425-015-0048-2.","journal-title":"J Immunother Cancer"},{"key":"130_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","volume":"3","author":"H Laubli","year":"2015","unstructured":"Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11. https:\/\/doi.org\/10.1186\/s40425-015-0057-1.","journal-title":"J Immunother Cancer"},{"issue":"19","key":"130_CR18","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/eht066","volume":"34","author":"FP Brouwers","year":"2013","unstructured":"Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34(19):1424\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/eht066 (Epub 2013 Mar 6. PMID: 23470495).","journal-title":"Eur Heart J"},{"issue":"4","key":"130_CR19","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1136\/hrt.2006.104067","volume":"94","author":"M Imazio","year":"2008","unstructured":"Imazio M, Cecchi E, Demichelis B, Chinaglia A, Ierna S, Demarie D, Ghisio A, Pomari F, Belli R, Trinchero R. Myopericarditis versus viral or idiopathic acute pericarditis. Heart. 2008;94(4):498\u2013501. https:\/\/doi.org\/10.1136\/hrt.2006.104067 (Epub 2007 Jun 17 PMID: 17575329).","journal-title":"Heart"},{"issue":"1","key":"130_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ahj.2009.05.010","volume":"158","author":"A Alonso","year":"2009","unstructured":"Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158(1):111\u20137. https:\/\/doi.org\/10.1016\/j.ahj.2009.05.010.","journal-title":"Am Heart J"},{"issue":"12","key":"130_CR21","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9.","journal-title":"Lancet Oncol"},{"issue":"21","key":"130_CR22","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. Circulation. 2017;136(21):2085\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030571.","journal-title":"Circulation"},{"issue":"12","key":"130_CR23","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","volume":"125","author":"O Oren","year":"2020","unstructured":"Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. Am J Cardiol. 2020;125(12):1920\u20136. https:\/\/doi.org\/10.1016\/j.amjcard.2020.02.016.","journal-title":"Am J Cardiol"},{"issue":"2","key":"130_CR24","first-page":"142","volume":"21","author":"M Paalani","year":"2011","unstructured":"Paalani M, Lee JW, Haddad E, Tonstad S. Determinants of inflammatory markers in a bi-ethnic population. Ethn Dis. 2011;21(2):142\u20139.","journal-title":"Ethn Dis"},{"issue":"10","key":"130_CR25","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.amjcard.2004.01.067","volume":"93","author":"MA Albert","year":"2004","unstructured":"Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women\u2019s Health Study). Am J Cardiol. 2004;93(10):1238\u201342. https:\/\/doi.org\/10.1016\/j.amjcard.2004.01.067.","journal-title":"Am J Cardiol"},{"issue":"1","key":"130_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/1055-9965.EPI-08-0705","volume":"18","author":"L Enewold","year":"2009","unstructured":"Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, et al. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 2009;18(1):215\u201322. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-0705.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"23","key":"130_CR27","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-17-0527","volume":"23","author":"KA Mitchell","year":"2017","unstructured":"Mitchell KA, Zingone A, Toulabi L, Boeckelman J, Ryan BM. Comparative Transcriptome Profiling Reveals Coding and Noncoding RNA Differences in NSCLC from African Americans and European Americans. Clin Cancer Res. 2017;23(23):7412\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0527.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"130_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/bjc.2014.555","volume":"112","author":"A D'Incecco","year":"2015","unstructured":"D\u2019Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crin\u00f2 L, Terracciano L, Cappuzzo F. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112(1):95\u2013102. https:\/\/doi.org\/10.1038\/bjc.2014.555.","journal-title":"Br J Cancer"},{"key":"130_CR29","doi-asserted-by":"publisher","unstructured":"Troiano, G., Caponio, V. C., Zhurakivska, K., Arena, C., Pannone, G., Mascitti, M., Santarelli, A., & Lo Muzio, L. (2018). High pd\u2010l1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for ORAL squamous CELLS carcinoma: A meta\u2010analysis of the literature. Cell Proliferation, 52(2). https:\/\/doi.org\/10.1111\/cpr.12537","DOI":"10.1111\/cpr.12537"},{"issue":"Supplement_7","key":"130_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/rheumatology\/kez308","volume":"58","author":"SC Weinmann","year":"2019","unstructured":"Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology. 2019;58(Supplement_7):59\u201367. https:\/\/doi.org\/10.1093\/rheumatology\/kez308.","journal-title":"Rheumatology"},{"issue":"16","key":"130_CR31","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"130_CR32","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(18)30457-1.","journal-title":"Lancet Oncol"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-022-00130-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-022-00130-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-022-00130-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T09:10:47Z","timestamp":1646989847000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-022-00130-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["130"],"URL":"https:\/\/doi.org\/10.1186\/s40959-022-00130-5","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]},"assertion":[{"value":"10 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Wake Forest University SOM IRB 00053003 and this document is void of all patient identifying information. As this is a retrospective study, no interventions were made.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}